Precision’s Schafer and Lotterman Define Financial Toxicity

Senior Vice President Jeremy Schafer and Chief Creative Officer Deborah Lotterman submit a new commentary to MedAd News,“Enriching the Patient Journey: When Cost Creates Side Effects.” In it, they describe the rise of a new dynamic in patient-centric healthcare—financial toxicity—in which a patient’s treatment choices are impacted by his or her financial reality.

To read the complete article, please click here (see page 29).

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.